Cambridge Healthtech Institute’s 2nd Annual

Advanced Diagnostics for Precision Oncology

Multi-Cancer Early Detection and Minimal Residual Disease Testing

March 7-8, 2023

Multi-cancer early detection and advanced cancer diagnostics promise to transform cancer treatment and save lives. Cambridge Healthtech Institute’s 2^nd Annual Advanced Diagnostics for Precision Oncology meeting convenes key stakeholders to discuss not only MCED and MRD emerging technologies, but also the business models, reimbursement and market access challenges, investment and partnering opportunities, and impact on the big pharma oncology models.

Coverage will include, but is not limited to:

Minimal residual disease detection
Multi-cancer early detection, advanced diagnostics, and population screening
Business model and market access for early detection diagnostics
Impact of early detection technologies on big pharma models
Market access, regulatory, and reimbursement considerations for MCED
Molecular characterization for targeted therapy selection
Predictive and prognostic cancer biomarkers and companion diagnostics
Integrating genomic and molecular testing into patient care

The deadline for priority consideration is July 29, 2022.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: